Počet záznamov: 1
trastuzumab emtanzín
SYS d000080044 LBL 00000cz--a2200181n--4500 005 20250606222909.7 008 200101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D02.540.505.495.500 065 $a D04.345.295.500.500 065 $a D12.776.124.486.485.114.224.060.875.500 065 $a D12.776.124.790.651.114.224.060.875.500 065 $a D12.776.377.715.548.114.224.200.875.500 066 $a 01 $c 03 150 $a trastuzumab emtanzín $x AD $x AE $x AN $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a Trastuzumab-DM1 $2 eng 450 $w v $a Trastuzumab-DM1 Conjugate $2 eng 450 $w v $a Trastuzumab Emtansine $2 eng 450 $w v $a Kadcyla $2 slo 450 $w v $a ado-trastuzumab emtanzín $2 slo 450 $w v $a trastuzumab-DM1 konjugát $2 slo 550 $7 sllk_us_auth*d000922 $Y Immunotoxins $w P $a imunotoxíny 550 $7 sllk_us_auth*d050257 $Y Tubulin Modulators $w P $a modulátory tubulínu 550 $7 sllk_us_auth*d000074322 $Y Antineoplastic Agents, Immunological $w P $a antineoplastiká imunologické 665 $a 2020 (2010) $2 eng 680 9-
$i Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination. $2 eng 750 -2
$a Ado-Trastuzumab Emtansine $2 eng 980 $x M
Počet záznamov: 1